Ovid Therapeutics Showcases Neurotherapeutics Pipeline Targeting Drug-Resistant Seizures and Neural Hyperexcitability

Ovid Therapeutics Inc. has provided an update on its neurotherapeutics pipeline targeting conditions driven by neural hyperexcitability. The company highlighted progress on multiple clinical programs, including OV329, a GABA-aminotransferase inhibitor being developed for drug-resistant adult focal onset seizures. Phase 1 results for OV329 demonstrated a strong safety profile and pharmacodynamic activity, with Phase 2a initiation expected in the second quarter of 2026 and topline results anticipated in mid-2027. Ovid also reported on OV350 IV, a first-in-human direct activator of KCC2, with Phase 1 topline findings expected in the fourth quarter of 2025. Other pipeline candidates include OV4071 for psychosis associated with Parkinson’s disease, Lewy body dementia, and schizophrenia, with regulatory submissions and Phase 1 studies planned for 2026, and OV4041 targeting generalized anxiety disorder and Rett syndrome, moving toward IND submission in late 2026. The company stated it has an anticipated cash runway into the second half of 2028, supporting advancement of these programs. You can access the full presentation through the link below. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ovid Therapeutics Inc. published the original content used to generate this news brief on November 14, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here